Liu et al. reported that ATF3 could promote the expression of PD-L1 through increasing its transcription and silencing ATF3 would enhance the proliferative inhibitory effect of ADORA1 antagonists on melanoma and non-small cell lung cancer xenografts [35]. Here, ATF3 is linked to non-small cell lung carcinoma.